Women's Health

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

GLP-1 receptor agonists expand treatment options for diabetes, weight loss, and more, showing promise in heart failure, kidney disease, and neuroprotection.

New studies reveal a modest, temporary increase in breast cancer risk linked to hormonal contraceptives, emphasizing the need for informed patient counseling.

Particularly, younger women with chronic kidney disease (CKD) experienced the greatest survival disadvantage.

Pharmacists Can Educate Patients About Symptoms of Menopause, Associated Chronic Conditions, and Management Options

Natural strategies and OTC options can help manage menopause symptoms, from hot flashes to mood changes, for a smoother transition.

Elinzanetant Showed Smaller Reductions in Bone Mineral Density Than Placebo

The Annual Meeting Highlighted Emerging Research on Hormone Therapy, Brain and Heart Health, Disparities in Menopause Care, and the Expanding Role of Pharmacists

FDA Approval Introduces a First-in-Class Neurokinin Receptor Agonist Shown to Reduce Vasomotor Symptom Frequency and Improve Sleep Quality in Postmenopausal Women

How can a natural biological evolution with so many consequences get relatively little attention from research and practice?

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

The FDA lifts the black box warning on hormone replacement therapy, empowering women with new options for managing menopause symptoms.

Maternal COVID-19 infection raises concerns about neurodevelopmental disorders in children, emphasizing the need for effective fever and infection management during pregnancy.

Research highlights significant barriers to contraceptive use and reproductive health management for women with chronic kidney disease (CKD), urging improved nephrology care.

Research highlights the link between earlier menopause, cardiac function, and brain health, emphasizing the need for sex-specific dementia risk strategies.

Research highlights the impact of provider type on menopause treatment, revealing a need for standardized education to improve care quality for women.

Elinzanetant, the first FDA-approved nonhormonal treatment for menopause-related vasomotor symptoms, offers women a new, effective relief option.

The authors wrote that their findings show a necessary update following early data from the Women’s Health Initiative.

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

New clinical trial results suggest G-CSF as a promising alternative for managing hot flashes in menopausal women, without the risks of traditional therapies.

Research highlights the impact of sleep disturbances and vasomotor symptoms (VMS) on HRQoL in women transitioning to menopausal period, emphasizing the need for effective management.

Explore how pharmacists can better support indigenous and Hispanic women during menopause through culturally sensitive care and family involvement.

When treating vasomotor symptoms (VMS), 15- and 20-mg doses of estetrol (E4) did not significantly hinder postmenopausal women’s blood pressure, including those with cardiovascular risks.

New research reveals how menopausal hormone therapy impacts cognitive health in postmenopausal women, highlighting the importance of administration routes and estrogen types.

Elinzanetant was effective in women with low vasomotor symptom (VMS) burden and those with endocrine therapy-caused VMS.